Compare DuPont de Nemours Inc (DD) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Novavax Inc — how do they compare? DuPont de Nemours Inc trades at $130.15 (market cap $17.89B), while Novavax Inc trades at $12.73 (market cap $1.82B). The key difference: DuPont de Nemours Inc is far larger — about 9.8× Novavax Inc's market cap, and DuPont de Nemours Inc pays a 1.81% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Novavax Inc for 59 Days on average.
| DD | NVAX | |
|---|---|---|
Market Cap | $17.89B | $1.82B |
Volume | 816,409 | 6,198,505 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $12.56 |
52-Week Low | $92.49 | $6.22 |
Typical Hold Time | 89 Days | 59 Days |
Enterprise Value | $19.28B | $1.39B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $130.00, down 0.82% on the day, with a neutral technical signal and mixed financial trends. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 contrast with a net loss of $779 million in 2025, though 2026 forecasts show a return to profitability. The company faces headwinds from PFAS litigation settlements and volatile cash flows, but innovation in areas like Tyvek and water technology supports long-term growth prospects.
The outlook for DD is cautiously optimistic, driven by secular growth in healthcare and water technologies, but weighed down by legal liabilities and margin pressures. Analyst consensus is bullish with a 58.54% buy rating, though the $95.00 price target suggests downside risk from current levels. Key risks include ongoing litigation costs and economic sensitivity in construction markets.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
